Dashboard
1
High Management Efficiency with a high ROCE of 3.19%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 9.42
3
Healthy long term growth as Net Sales has grown by an annual rate of 72.68% and Operating profit at 30.79%
4
With ROE of 1.02%, it has a attractive valuation with a 0.76 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
SEK 5,650 Million (Small Cap)
74.00
NA
351.15%
0.21
1.00%
0.83
Revenue and Profits:
Net Sales:
647 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.66%
0%
-7.66%
6 Months
-8.6%
0%
-8.6%
1 Year
-29.6%
0%
-29.6%
2 Years
-38.65%
0%
-38.65%
3 Years
-2.61%
0%
-2.61%
4 Years
-73.08%
0%
-73.08%
5 Years
-36.36%
0%
-36.36%
Swedencare AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
72.68%
EBIT Growth (5y)
30.79%
EBIT to Interest (avg)
9.42
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.14
Sales to Capital Employed (avg)
0.27
Tax Ratio
37.58%
Dividend Payout Ratio
40.14%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.19%
ROE (avg)
2.39%
Valuation key factors
Factor
Value
P/E Ratio
74
Industry P/E
Price to Book Value
0.76
EV to EBIT
38.71
EV to EBITDA
13.96
EV to Capital Employed
0.80
EV to Sales
2.62
PEG Ratio
NA
Dividend Yield
376.73%
ROCE (Latest)
2.08%
ROE (Latest)
1.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
646.70
630.50
2.57%
Operating Profit (PBDIT) excl Other Income
95.00
139.10
-31.70%
Interest
18.90
21.90
-13.70%
Exceptional Items
-5.00
-0.20
-2,400.00%
Consolidate Net Profit
-6.90
20.90
-133.01%
Operating Profit Margin (Excl OI)
35.40%
94.20%
-5.88%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 2.57% vs 10.21% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -133.01% vs 28.22% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,530.20
2,324.60
8.84%
Operating Profit (PBDIT) excl Other Income
537.40
475.00
13.14%
Interest
82.20
93.20
-11.80%
Exceptional Items
-1.70
-0.40
-325.00%
Consolidate Net Profit
98.90
58.60
68.77%
Operating Profit Margin (Excl OI)
87.50%
71.10%
1.64%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.84% vs 27.06% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 68.77% vs -37.99% in Dec 2023
About Swedencare AB 
Swedencare AB
Pharmaceuticals & Biotechnology
Swedencare publ AB is a Sweden-based company, which is mainly involved in the veterinary supplies industry. The Company operates as a provider of various products for animal health, distributed to veterinarians, pet stores and pharmacies. It operates through four subsidiaries, namely SDC Distribution for Scandinavian countries, Buccosante located in France, Informpet in the United Kingdom and SwedencareUSA in the United States. The Company's product portfolio includes ProDen product family, which consists of ProDen PlaqueOff Teeth and Gums, ProDen PlaqueOff Powder, ProDen PlaqueOff Powder Cat and ProDen PlaqueOff Dental Bites, among others. The products are available at veterinary clinics, pet retailers, pharmacies, health stores and dentist practices.
Company Coordinates 
Company Details
Medeon Science Park , MALMO None : 205 12
Registrar Details






